Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Oral contraceptives and the risk of venous thrombosis.N Engl J Med. 2001; 344: 1527-1535
- Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use.Eur Heart J. 2002; 23: 984-990
- Incidence of venous thromboembolism in young Swedish women and possibly preventable cases among combined oral contraceptive users.Acta Obstet Gynecol Scand. 2004; 83: 674-681
- Oral contraceptives and venous thromboembolism: a five-year national case���control study.Contraception. 2002; 65: 187-196
- Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives.Obstet Gynecol. 2007; 110: 587-593
- The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation.Contraception. 2007; 75: 344-354
- Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysis.Contraception. 2001; 64: 125-133
- Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.BMJ. 2001; 323: 131-134
- Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case���control study using United States claims data.BMJ. 2011; 340: d2151
- Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case���control study based on UK General Practice Research Database.BMJ. 2011; 340: d2139
- Hormonal contraception and risk of venous thromboembolism: national follow-up study.BMJ. 2009; 339: b2890
- Thromboembolic disease and present oral contraception.Clin Appl Thromb Hemost. 2003; 9: 45-51
- Recurrence of venous thromboembolic disease and use of oral contraceptives.BMJ. 1974; 1: 215-217
- Thrombophilia, clinical factors, and recurrent venous thrombotic events.JAMA. 2005; 293: 2352-2361
- The risk of recurrent venous thromboembolism in men and women.N Engl J Med. 2004; 350: 2558-2563
- The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients.Haematologica. 2007; 92: 199-205
- Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study.Lancet. 2003; 362: 523-526
- WHO Library Cataloguing-in-Publication Data, Geneva2004: 176 Medical eligibility criteria for contraceptive use. 3rd ed.
- Genetic susceptibility to venous thrombosis.N Engl J Med. 2001; 344: 1222-1231
- Genetic analysis, phenotypic diagnosis, and risk of venous thrombosis in families with inherited deficiencies of protein S.Blood. 2000; 95: 1935-1941
- Plasma levels of protein S, protein C, and factor X: effects of sex, hormonal state and age.Thromb Haemost. 1995; 74: 1271-1275
- A study of protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state.Br J Haematol. 2001; 113: 636-641
- Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study.Thromb Haemost. 2010; 104: 498-503
- Progestogen-only contraception in women at high risk of venous thromboembolism.Contraception. 2004; 70: 437-441
- Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment.Thromb Res. 2005; 116: 301-306
���This work was supported by public funds (Centre Hospitalier de Clermont-Ferrand, Facult�� de M��decine, Universit�� de Clermont-Ferrand 1).
������Conflict-of-interest disclosure: The authors declare no competing financial interests.